Powered by

Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis

Mar 01, 2018 - Thomson Reuters ONE

Novartis International AG / Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

- Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis

- Collaboration combines Novartis' leadership in biomedical ...